Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006922 | 0.92 | GNRHR (0.85) | GNRHRMEN1KMT2A | |
| SCHEMBL7006717 | 0.91 | GNRHR (0.89) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7498171 | 0.91 | GNRHR (0.88) | GNRHRMEN1KMT2A | |
| SCHEMBL7015901 | 0.91 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| SCHEMBL7496136 | 0.91 | GNRHR (0.82) | GNRHRMEN1KMT2A | |
| SCHEMBL7007954 | 0.91 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8165522 | 0.91 | GNRHR (0.79) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7494036 | 0.90 | GNRHR (0.99) | GNRHRMEN1KMT2A | |
| SCHEMBL7827375 | 0.90 | GNRHR (0.85) | GNRHRMEN1KMT2A | |
| SCHEMBL7009439 | 0.89 | GNRHR (0.77) | GNRHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0756599-B1 | BICYCLIC THIOPHENE DERIVATIVES AND USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-11-26 | — | — | EP | claimed |
| EP-1229906-A2 | MESOPROGESTINS FOR THE TREATMENT AND PREVENTION OF BENIGN HORMONE DEPENDENT GYNECOLOGICAL DISORDERS | Jenapharm GmbH & Co. KG (DE) | 2002-08-14 | — | — | EP | claimed |
| WO-2001015679-A2 | MESOPROGESTINS FOR THE TREATMENT AND PREVENTION OF BENIGN HORMONE DEPENDENT GYNECOLOGICAL DISORDERS | JENAPHARM GMBH & CO. KG (DE) | 2001-03-08 | — | — | WO | claimed |
| US-8193252-B1 | Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders | Bayer Pharma AG (DE) | 2012-06-05 | — | — | US | disclosed |
| US-7309691-B2 | Combined pharmaceutical preparation containing LHRH-analogous substances and anti estrogens for treating gynaecological disorders | ACHERING AKTIENGESELLSCHAFT (DE) | 2007-12-18 | — | — | US | disclosed |
| EP-0756599-B1 | BICYCLIC THIOPHENE DERIVATIVES AND USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-6514988-B1 | A pregnancy controlling agent and a menstrual cycle controlling agent; useful as an agent of spawning promotion in fish | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020198155-A1 | Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-26 | — | — | US | disclosed |
| EP-1229906-A2 | MESOPROGESTINS FOR THE TREATMENT AND PREVENTION OF BENIGN HORMONE DEPENDENT GYNECOLOGICAL DISORDERS | Jenapharm GmbH & Co. KG (DE) | 2002-08-14 | — | — | EP | disclosed |
| US-20020032156-A1 | Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-03-14 | — | — | US | disclosed |
| US-6329388-B2 | GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E.G., SEX HORMONE-DEPENDENT CANCERS (E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6262267-B1 | HAS GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E,G., SEX HORMONE-DEPENDENT CANCERS E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-17 | — | — | US | disclosed |
| US-20010001104-A1 | Thienopyridine compounds, their production and use | FURUYA SHUICHI (JP) | 2001-05-10 | — | — | US | disclosed |
| WO-2001015679-A2 | MESOPROGESTINS FOR THE TREATMENT AND PREVENTION OF BENIGN HORMONE DEPENDENT GYNECOLOGICAL DISORDERS | JENAPHARM GMBH & CO. KG (DE) | 2001-03-08 | — | — | WO | disclosed |
| US-6187788-B1 | THIENO(2,3-B)(DIHYDRO)PYRIDINE DERIVATIVES; GONADOTROPIN-RELEASING HORMONE ANTAGONISTS; ANTICARCINOGENIC AGENTS; SEXUAL AND UROGENITAL DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6180792-B1 | DRUGS, ANTISECRETORY AGENTS AND HORMONE INHIBITORS FOR LH-RH | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-30 | — | — | US | disclosed |
| US-6048863-A | SEXUAL DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| US-5817819-A | GONADOTROPIN-RELEASING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0756599-A1 | BICYCLIC THIOPHENE DERIVATIVES AND USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995028405-A1 | BICYCLIC THIOPHENE DERIVATIVES AND USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001104-A1 | Thienopyridine compounds, their production and use | PRLHR, PGR, GNRHR | GNRHR 3/4885MEN1 517/4885KMT2A 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.